Endoscopic remission rates at week 26 and 52 were higher in TNF-antagonist naïve (9.6 and 25%) vs. TNF-antagonist exposure (5.5 and 8.3%), higher in moderate disease (SES-CD 7-15) (17 and 20.7%) vs. severe disease (SES-CD > 15) (6.7 and 14.8%), and higher in shorter disease duration (<1 year) (37.5 and 100%) vs. longer disease duration (≥7 years) (7.1 and 11.5%). The gene discussed is TNF; the disease is Cowden disease.